Europe Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Market Introduction

The European neoantigens market is divided into Germany, the UK, France, Italy, and Spain. The region holds a significant market share in the global neoantigens market. The market growth is attributed due to the increasing research & development in the bioinformatics field across the countries. Also, the rising incidence of cancer is likely to raise the demand for neoantigens targeted. Germany is much ahead in terms of the healthcare industry. It has the presence of market leaders from across the world. Also, there are well-established players across the country that is contributing to the overall healthcare industry. The number of cancer cases in Germany have increased due to risk factors like smoking, unhealthy diet, or infection. As per the Globocan 2020, the total number of cancer cases was 628,519 in 2020, of which 344,451 were in males and 284,068 female cases. The top five cancer types in Germany are breast, lung, prostate, colon, bladder, and other cancer. Furthermore, increasing prevalence of cancer has led to the development of increased number of studies on cancer in Germany which is likely to favor market growth. For instance, In November 2019, NEC Corporation and VAXIMM AG, a privately held, Swiss-German biotech company that is dedicated in developing vaccines for patients suffering from cancer collaborated to develop novel personalized neoantigen cancer vaccines. Similarly, in 2017, a proof-of-principle studies by a team in Europe demonstrated that neoantigen vaccines can direct immune responses against cancer cells in patients with recurrent melanoma. In the European study, researchers in Germany and Austria created a vaccine containing a mix of 10 RNA molecules encoding neoantigen peptides, which boosted immune activity against tumours in 9 out of 13 patients in the study. Thus, increased offering for neoantigens is likely to influence the market's growth in the forecasted period.

In Europe, there is an exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of May 6^th, 2020, Spain, the UK, Italy, Germany, and France recorded 3,551,262; 4,425,940; 4,070,400; 3,469,448; and 5,706,378, COVID-19 cases, respectively, and the deaths toll is also high in these countries. As per the news article, due to COVID-19 emergency, access to chemotherapy, scans, transplants, and surgery has become difficult for thousands of cancer patients in Italy. According to the research led by Codice Viola, charity that supports pancreatic cancer patients found that more than 500 breast or pancreatic patients’ appointments for chemotherapy or radiotherapy were postponed. Additionally, 64% of surgical procedures were postponed and more than half of the follow-up appointments rescheduled. Additionally, in Europe, many of the cancer vaccine development companies have been directed to develop COVID-19 vaccine. For instance, on April 2020, NEC announced that, after its neoantigen cancer vaccine project, it is planning to develop COVID-19 vaccine using AI with a close collaboration with NOI, a biotechnology subsidiary located in Oslo, Norway. Also, patient enrollment in clinical trials has been significantly declined. These factors are likely to have negative impact on the market growth.

Get more information on this report :

Market Overview and Dynamics

The neoantigens market in Europe is expected to grow from US$ 86,165.00 thousand in 2023 to US$ 341,855.35 thousand by 2028; it is estimated to grow at a CAGR of 31.7% from 2023 to 2028. Use of AI in neoantigen vaccine development; private organizations and companies as well as government associations are equally participating in the development of immunotherapy methods by integrating IT with life sciences. Healthcare IT and neoantigen market players are integrating artificial intelligence (AI) technology with neoantigens to identify patient-specific immunogenic cancer mutations. In May 2020, NEC Corporation, an IT and network technologies company, and Transgene, a company involved in the development of virus-based immunotherapies for cancer treatment, announced to publish their findings in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual Annual Meeting II) in June 2020. The companies were looking forward to announcing data related to a prediction algorithm that can be used to customize an individualized therapeutic vaccine TG4050 for patients as per their immunogenic cancer mutation is accurate in June 2020 at AACR Virtual Annual Meeting II. The customization of TG4050 would be more specific, and it would be possible for a large set of candidate mutations. The TG4050 was designed by using the myvac technology of Transgene and Neoantigen Prediction System of NEC. The prediction system is an advanced AI technology that has been in use in the field of oncology. The TG4050 is developed to treat solid tumors and is currently in the Phase 1 clinical trial in the US and Europe. Thus, the integration of AI with neoantigen vaccine research is emerging as a key trend in the neoantigen market. This is bolstering the growth of the neoantigens market.

Key Market Segments

Based on treatment, the market is segmented into combination therapy, and mono therapy. In 2023, the combination therapy segment is estimated to have the largest share of the market. Based on therapeutic specialty, the market is segmented into gastrointestinal cancer, lung cancer, solid tumor, urinary systems cancers, melanoma, head and neck cancer, and others. In 2023, the gastrointestinal cancer segment is estimated to hold the largest share of the market.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the neoantigens market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Achilles Therapeutics plc, Frame Cancer Therapeutics, Genocea, Immunicum AB, Medigene AG, and Moderna, Inc among others.

Reasons to buy report

To understand the Europe neoantigens market landscape and identify market segments that are most likely to guarantee a strong return
Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe neoantigens market
Efficiently plan M&A and partnership deals in Europe neoantigens market by identifying market segments with the most promising probable sales
Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe neoantigens Market
Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

EUROPE NEOANTIGENS MARKET SEGMENTATION

By Treatment

Combination Therapy
Mono Therapy

By Therapeutic Specialty

By Country

Company Profiles

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Neoantigens Market – By Treatment

1.3.2 Europe Neoantigens Market – By Therapeutic Specialty

1.3.3 Europe Neoantigens Market– By Country

2. Europe Neoantigens Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Neoantigens Market– Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 Europe PEST Analysis

4.3 Expert Opinion

5. Neoantigens Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Evolution in Neoantigen Vaccines Against Cancer

5.1.2 Rising Prevalence of Cancer

5.2 Market Restraints

5.2.1 Possible Side Effects Associated with Neoantigen Vaccines

5.3 Market Opportunities

5.3.1 Application of Next-generation Sequencing for Neoantigen Identification

5.4 Future Trends

5.4.1 Use of AI in Neoantigen Vaccine Development

5.5 Impact Analysis

6. Neoantigens Market – Europe Analysis

6.1 Europe Neoantigens Market Revenue Forecast and Analysis

7. Europe Neoantigens Market Analysis – By Treatment

7.1 Overview

7.2 Europe Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

7.3 Combination Therapy

7.3.1 Overview

7.3.2 Combination Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

7.4 Mono Therapy

7.4.1 Overview

7.4.2 Mono Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8. Europe Neoantigens Market Analysis – By Therapeutic Specialty

8.1 Overview

8.2 Europe Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

8.3 Gastrointestinal Cancer

8.3.1 Overview

8.3.2 Gastrointestinal Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.4 Lung Cancer

8.4.1 Overview

8.4.2 Lung Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.5 Solid Tumors

8.5.1 Overview

8.5.2 Solid Tumors: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.6 Urinary System Cancers

8.6.1 Overview

8.6.2 Urinary System Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.7 Melanoma

8.7.1 Overview

8.7.2 Melanoma: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.8 Head and Neck Cancers

8.8.1 Overview

8.8.2 Head and Neck Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.9 Others

8.9.1 Overview

8.9.2 Others: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

9. Europe Neoantigens Market – Country Analysis

9.1 Europe: Neoantigens Market

9.1.1 Overview

9.1.2 Europe: Neoantigens Market, by Country, 2023 & 2028(%)

9.1.3 Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.1 Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.2 Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.3 Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.4 France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.1 France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.2 France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.3 France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.5 UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.1 UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.2 UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.3 UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.6 Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.1 Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.2 Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.6.3 Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.7 Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.1 Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.2 Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.7.3 Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

9.1.8 Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.1 Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.2 Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

9.1.8.3 Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

10. Impact Of COVID-19 Pandemic on Europe Neoantigens Market

10.1 Europe: Impact Assessment of COVID-19 Pandemic

11. Neoantigens Market–Industry Landscape

12. Company Profiles

12.1 Achilles Therapeutics plc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Frame Cancer Therapeutics

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Genocea

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Immunicum AB

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Medigene AG

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Moderna, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

13. Appendix

13.1 About the Insight Partners

13.2 Glossary of Terms

LIST OF TABLES

Table 1. New Cancer Cases Registered Worldwide, 2020

Table 2. Europe Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

Table 3. Incidence, Mortality and Prevalence by cancer site, 2020, Germany

Table 4. Germany: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 5. Germany: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 6. Incidence, Mortality and Prevalence by cancer site, 2020, France

Table 7. France: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 8. France: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 9. UK: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 10. UK: Neoantigens Market, Application – Revenue and Forecast to 2028 (USD Thousand)

Table 11. Incidence, Mortality and Prevalence by cancer site, 2020, Italy

Table 12. Italy: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 13. Italy: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 14. Incidence, Mortality and Prevalence by cancer site, 2020, Spain

Table 15. Spain: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 16. Spain: Neoantigens Market, Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 17. Rest of Europe: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 18. Rest of Europe: Neoantigens Market, by Therapeutic Application – Revenue and Forecast to 2028 (USD Thousand)

Table 19. Market Developments Done By Companies

Table 20. Glossary of Terms, Neoantigens Market

LIST OF FIGURES

Figure 1. Europe Neoantigens Market Segmentation

Figure 2. Europe Neoantigens Segmentation, By Country

Figure 3. Europe Neoantigens Market Overview

Figure 4. Combination Therapy Segment Holds Largest Share of Europe Neoantigens Market

Figure 5. Germany to Show Remarkable Growth During Forecast Period

Figure 6. Europe: PEST Analysis

Figure 7. Expert Opinion

Figure 8. Europe Neoantigens Market Impact Analysis of Drivers and Restraints

Figure 9. Europe Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028

Figure 10. Europe Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

Figure 11. Combination Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 12. Mono Therapy: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 13. Europe Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

Figure 14. Gastrointestinal Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 15. Lung Cancer: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 16. Solid Tumors: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 17. Urinary System Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 18. Melanoma: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 19. Head and Neck Cancers: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 20. Others: Europe Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 21. Europe: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 22. Europe: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 23. Germany: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 24. France: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 25. UK: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 26. Italy: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 27. Spain: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 28. Rest of Europe: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 29. Impact of COVID-19 Pandemic in European Country Markets

To understand the Europe neoantigens market landscape and identify market segments that are most likely to guarantee a strong return
Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe neoantigens market
Efficiently plan M&A and partnership deals in Europe neoantigens market by identifying market segments with the most promising probable sales
Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe neoantigens Market
Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Europe Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software and Serv..	May 2022
Europe Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Electric P..	May 2022
Europe In-Office Teeth Whitening Products Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Double-Syringe Mixing Configurat..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000

$3000

GET FREE SAMPLE PDF

Inquire before Buying Inquire for Discount

Subscription Member Price: FREE

Get Subscription

Europe Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

Request for Free Sample